ImmunityBio Faces FDA Enforcement Risk as Stock Tests $6.88 Support Amid Promotional Fallout

The market's violent reaction began with a single date: March 13, 2026. That's when the FDA's Office of Prescription Drug Promotion (OPDP) issued a formal warning letter to ImmunityBio. The letter didn't mince words. It cited two specific promotional materials as "false or misleading": a direct-to-consumer TV ad and a January podcast episode titled "Is the FDA BLOCKING Life Saving Cancer Treatments?" The podcast originally aired on The Sean Spicer Show on January 19, 2026 and featured company executives, including CEO Richard Adcock and Executive Chairman Patrick Soon-Shiong.

The FDA's core argument was straightforward. Both materials, the agency said, created a misleading impression that Anktiva could cure and prevent all cancer, when the drug is only approved for treating a specific type of bladder cancer in combination with BCG therapy. The promotional materials suggested Anktiva could cure and prevent all types of cancer. This is a classic case of a product being promoted for uses beyond its approved label, a fundamental violation that triggers regulatory and market alarms.

The immediate market impact was brutal. Shares plunged as much as 30% when markets opened in New York on Tuesday, which was March 24. That's a classic panic sell-off, where fear of regulatory action and potential sales restrictions overwhelms any fundamental analysis. The stock did manage a partial recovery, but the damage was done. The move was swift and severe, a textbook reaction to a high-profile enforcement action.

In response, ImmunityBio acted fast. The company confirmed it had removed the identified podcast from its corporate website and formally requested its removal from third-party platforms. More importantly, it submitted a comprehensive response to the FDA within the 15-working-day window. The company's statement also clarified that the TV ad cited in the letter was never aired, a key factual point for the technical narrative. This immediate damage control was necessary, but it didn't stop the initial price collapse. The setup for technical analysis is clear: a sharp, negative breakout from recent support, driven by a clear fundamental violation. The next step is to map the new supply and demand zones.

Price Action and Supply/Demand Dynamics

The technical picture shows a stock caught in a tug-of-war between the aftermath of a major sell-off and the lingering momentum of a historic rally. The 20-day change of -18.53% confirms a significant pullback from the peak. But that drop needs context. It's a correction from a 120-day gain of 199.2%. In other words, the market is digesting a massive run-up, and the FDA warning acted as the catalyst for a sharp reset.

Volume and volatility tell the story of intense short-term interest. On April 6, the stock saw volume of 14.22M shares and a daily volatility of 6.831%. That's a clear signal of high uncertainty and active trading as traders position for the next move. The amplitude of 6.583% also shows wide intraday swings, typical of a stock testing new support and resistance levels.

Price action reveals a contested range. The current price is near $7.30, which sits well below the 52-week high of $12.43 but above the low of $6.88. This creates a key supply zone just above the recent low and a demand zone near the current price. The stock is bouncing between these levels, with sellers likely testing the $6.88 floor and buyers defending the $7.30 area. The recent 2.24% pop on the day suggests buyers are stepping in, but the overall negative 20-day trend shows the bears still control the broader direction. The setup is one of a volatile, range-bound market where the next breakout-up or down-will likely be decisive.

Catalysts and Key Levels to Watch

The immediate technical battle is set. The stock is trading near $7.30, a level that now acts as a key demand zone. The primary near-term catalyst is the FDA's response to ImmunityBio's comprehensive submission, which was filed in late March. The agency has acknowledged the company's corrective actions, including the removal of the cited podcast and its commitment to enhanced compliance protocols. The company has submitted a comprehensive response to the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP). A positive resolution here could stabilize the stock and halt the downtrend. Conversely, any further enforcement action would likely trigger a new wave of selling pressure.

The critical technical level to watch is the recent low of $6.88. A confirmed break below that mark would invalidate the current bounce and signal that sellers have taken control. That move would open the path toward the next major support zone, likely in the $6.00 to $5.50 range. Given the stock's 20-day decline of 18.53%, a deeper drop is a real risk if the promotional issue isn't fully resolved. Traders should monitor volume on any move below $6.88; heavy selling would confirm the breakdown.

For the longer-term fundamental driver, the focus shifts to the drug's pipeline. The supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG in papillary NMIBC remains a critical catalyst. The FDA has acknowledged receipt of the resubmitted filing, which includes updated long-term follow-up data. The FDA has acknowledged receipt of the resubmitted filing. Success here would expand the drug's label and address a large patient population, providing a fundamental tailwind that could eventually outweigh the promotional setback. However, that's a forward-looking event, not a near-term price mover.

The bottom line for traders is a clear setup: watch the $6.88 level for a decisive break. The FDA response is the immediate trigger for a reversal, while the sBLA outcome is the longer-term game-changer. For now, the stock is range-bound, and the next major move will be dictated by which catalyst comes first.